The four meta-analyses 134,135,136,137 were successively updated to incorporate upcoming trials, so that the most recent 134 included seven RCTs 138,139,140,141,142,143,144
Interaction with insulin Januvia can interact with insulin, which is used to treat type 2 diabetes
This variability may impact the overall consistency of the findings and the generalizability of our results
Choose Retatrutide If: Maximum weight loss is the primary goal Previous GLP-1 agonists produced significant nausea (GIP component may help) No specific liver health concerns requiring treatment Tolerance for slightly higher GI side effects during titration Response to dual agonists (like tirzepatide) has been positive Choose Survodutide If: Liver health concerns exist (fatty liver, MASH, elevated liver enzymes) Moderate weight loss goals rather than maximum efficacy priority Interest in potential cardiovascular outcome benefits (CVOT data pending) Preference for a compound with FDA Breakthrough Therapy designation Plans to potentially transition to approved medication once available For most people focused primarily on weight loss, Retatrutide presents the stronger option based on available data
